ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

26,250Medicare Part D Prescriptions Filled, Including Refills

Rank: 23 out of 972

$1.08M Total Retail Price of All Prescriptions

Rank: 53 out of 972

996 Patients Receiving at Least One Drug in Part D
89%Patients 65 Years and Older
23% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Missouri
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 996 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

11% of this provider’s 996 patients filled at least one prescription for a schedule three drug, compared to an average of 12%.

Risky Drugs to Seniors

2% of this provider’s 24,306 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

18% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$41 was the average price of a prescription from this provider, compared to $56 among peers.

Prescriptions per Patient

26 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Missouri
SIMVASTATIN 1,052 1,005 1 2
LEVOTHYROXINE SODIUM 837 782 2 3
LISINOPRIL 805 753 3 1
PRAVASTATIN SODIUM 792 706 4 20
AMLODIPINE BESYLATE 782 745 5 4
OMEPRAZOLE 766 704 6 5
FUROSEMIDE 624 572 7 7
GABAPENTIN 577 534 8 14
ATORVASTATIN CALCIUM 552 507 9 11
HYDROCODONE-ACETAMINOPHEN 526 423 S3 10 6
WARFARIN SODIUM 500 479 11 12
LOSARTAN POTASSIUM 455 420 12 17
METFORMIN HCL 428 377 13 8
TRAMADOL HCL 413 385 14 15
ATENOLOL 412 397 15 18
METOPROLOL TARTRATE 408 387 16 9
GLIMEPIRIDE 385 356 17 34
HYDROCHLOROTHIAZIDE 374 359 18 10
RANITIDINE HCL 338 303 19 24
LISINOPRIL-HYDROCHLOROTHIAZIDE 310 294 20 32
ZOLPIDEM TARTRATE 290 252 21 23
CLOPIDOGREL 273 253 22 37
PREDNISONE 255 232 23 40
CARVEDILOL 255 237 23 21
SPIRONOLACTONE 254 251 25 54
ALLOPURINOL 250 250 26 28
FLUTICASONE PROPIONATE 241 221 27 31
DONEPEZIL HCL 240 240 28 26
METOPROLOL SUCCINATE 236 217 29 16
POTASSIUM CHLORIDE 235 221 30 13
LOSARTAN-HYDROCHLOROTHIAZIDE 223 194 31 61
TAMSULOSIN HCL 218 218 32 29
PLAVIX 215 207 33 55
MELOXICAM 213 178 34 36
LOVASTATIN 208 197 35 22
OXYBUTYNIN CHLORIDE 197 191 36 97
ALENDRONATE SODIUM 182 172 37 27
MIRTAZAPINE 168 165 38 46
CEPHALEXIN 150 144 39 124
LANTUS 149 148 40 44
AMLODIPINE BESYLATE-BENAZEPRIL 149 131 40 114
ADVAIR DISKUS 148 132 42 45
CITALOPRAM HBR 148 135 42 19
CARBIDOPA-LEVODOPA 146 127 44 87
PANTOPRAZOLE SODIUM 142 130 45 41
TRIAMTERENE-HCTZ 140 133 46 39
CYCLOBENZAPRINE HCL 139 106 R 47 53
METHYLPREDNISOLONE 138 133 48 119
OXYBUTYNIN CHLORIDE ER 134 134 49 128
KLOR-CON 10 129 126 50 68
AZITHROMYCIN 125 115 51 42
TRAZODONE HCL 123 116 52 35
ISOSORBIDE MONONITRATE ER 120 108 53 43
DIOVAN 119 110 54 48
FINASTERIDE 118 114 55 77
TRAMADOL HCL-ACETAMINOPHEN 118 96 55 155
OXYCODONE-ACETAMINOPHEN 117 111 S2 57 80
SULFAMETHOXAZOLE-TRIMETHOPRIM 114 109 58 109
HYDRALAZINE HCL 113 105 59 69
SERTRALINE HCL 112 110 60 25
DIGOXIN 111 111 61 52
PROPRANOLOL HCL 105 105 62 118
TRIAMCINOLONE ACETONIDE 104 91 63 134
INSULIN SYRINGE 102 99 64 84
PROAIR HFA 101 78 65 47
FELODIPINE ER 99 99 66 145
PAROXETINE HCL 96 94 67 64
GLIPIZIDE 93 85 68 59
ESCITALOPRAM OXALATE 93 85 68 65
ENALAPRIL MALEATE 91 88 70 50
TIZANIDINE HCL 90 71 71 143
KLOR-CON M20 89 85 72 78
CARISOPRODOL 86 85 R 73 110
BENAZEPRIL HCL 85 81 74 88
COMBIVENT 84 59 75 94
POLYETHYLENE GLYCOL 3350 82 75 76 67
NAPROXEN 81 72 77 71
LEVOFLOXACIN 81 79 77 98
CIPROFLOXACIN HCL 81 76 77 63
TORSEMIDE 79 77 80 131
VENTOLIN HFA 77 68 81 162
JANTOVEN 74 74 82 160
SPIRIVA 72 72 83 56
NABUMETONE 70 64 84 200
DILTIAZEM ER 69 69 85 129
AMOXICILLIN 67 54 86 121
VENLAFAXINE HCL ER 66 60 87 107
SINGULAIR 65 60 88 81
TERAZOSIN HCL 64 51 89 120
ATENOLOL-CHLORTHALIDONE 64 60 89 249
NEXIUM 63 56 91 30
CELEBREX 62 62 92 85
DILTIAZEM 24HR CD 61 61 93 74
DIOVAN HCT 60 60 94 122
CYMBALTA 60 45 94 49
NAMENDA 59 59 96 38
CILOSTAZOL 57 57 97 239
HYDROXYZINE HCL 55 38 R 98 208
GLYBURIDE 55 55 R 98 70
DOXYCYCLINE HYCLATE 54 50 100 117
BUTALB-CAFF-ACETAMINOPH-CODEIN 54 35 S3 R 100 476
NOVOLIN 70-30 53 53 102 213
FENOFIBRATE 52 46 103 66
FENTANYL 52 52 S2 103 89
JANUVIA 52 49 103 75
ACTOS 52 49 103 163
VERAPAMIL ER 51 51 107 108
VESICARE 51 51 107 171
NYSTATIN-TRIAMCINOLONE 50 45 109 319
BUPROPION HCL SR 50 38 109 148
BUSPIRONE HCL 50 40 109 105
CLOBETASOL PROPIONATE 50 39 109 303
GEMFIBROZIL 50 50 109 93
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 24, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.